Background: lack of knowledge and awareness of COVID-19 and radiation safety among healthcare professionals will adversely affect their health and the patients’ safety due to unnecessary radiation exposure and rapid spread of COVID-19. The purpose of this study is to evaluate the knowledge and the awareness of both domains; COVID-19 and radiation awareness in one survey study. 

A recent article published by Abbas et al. in the Journal of Biomedicine and Pharmacotherapy systematically revealed about the vaccines developed against the recent pandemic agents SARS-CoV-2 and its variants [1]. The authors insightfully provided an overview on the distinct features of the SARS-CoV-2 new variants, the associated mortality rate, hospitalization, re-infection and finally the efficacy of different vaccines.

The advent of immune checkpoint inhibitors (ICI) targeting CTLA-4 and PD-1/PD-L1 pathways has revolutionized cancer treatment with significantly improved outcomes across a spectrum of cancers [1,2]. Although ICI therapy offers significant clinical benefits, these treatments can also lead to various immune-related adverse events (irAEs) that may negatively impact patient outcomes. Although the precise mechanism of irAE is not fully understood, they demonstrate many clinical features similar to autoimmune diseases. IRAEs are thought to result from bystander effects of activated T-cells, cross-reactivity between tumor and host tissues, and the role of the gut microbiome in immune activation [3].

Activating innate immune signaling in tumor cells to enhance anti-tumor immunity and increase T cell-mediated killing is the core objective of tumor immunotherapy. PRMT1, one of the most crucial PRMTs, plays a critical role in tumor progression and innate immunity. Recent research revealed that PRMT1 can inhibit the enzymatic activity of cGAS in part through PRMT1-mediated Arg methylation, thereby suppressing the anti-tumor immune response of cells. As such, inhibiting or knocking down PRMT1 can synergistically enhance the efficacy of anti-PD-1 immunotherapy by activating the cGAS-STING signaling pathway. Here, we provide a comprehensive description of the two key signaling components, PRMT1 and cGAS, in the PRMT1-cGAS-STING signaling pathway for therapeutic intervention to augment anti-tumor immunity. By understanding the specific physiological functions and regulatory mechanisms of PRMT1.

Aligned with the Innovative Medicines Initiative (IMI) ConcePTION project’s goal of advancing drug safety research in pregnancy, we explored the feasibility of employing a standardized list of core data elements (CDEs) and statistical outputs to harmonize data collection and analysis across various study partners.